» Articles » PMID: 23691303

Hybrid Coronary Revascularization As a Safe, Feasible, and Viable Alternative to Conventional Coronary Artery Bypass Grafting: What is the Current Evidence?

Overview
Publisher Wiley
Specialty General Surgery
Date 2013 May 22
PMID 23691303
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

The "hybrid" approach to multivessel coronary artery disease combines surgical left internal thoracic artery (LITA) to left anterior descending coronary artery (LAD) bypass grafting and percutaneous coronary intervention of the remaining lesions. Ideally, the LITA to LAD bypass graft is performed in a minimally invasive fashion. This review aims to clarify the place of hybrid coronary revascularization (HCR) in the current therapeutic armamentarium against multivessel coronary artery disease. Eighteen studies including 970 patients were included for analysis. The postoperative LITA patency varied between 93.0% and 100.0%. The mean overall survival rate in hybrid treated patients was 98.1%. Hybrid treated patients showed statistically significant shorter hospital length of stay (LOS), intensive care unit (ICU) LOS, and intubation time, less packed red blood cell (PRBC) transfusion requirements, and lower in-hospital major adverse cardiac and cerebrovascular event (MACCE) rates compared with patients treated by on-pump and off-pump coronary artery bypass grafting (CABG). This resulted in a significant reduction in costs for hybrid treated patients in the postoperative period. In studies completed to date, HCR appears to be a promising and cost-effective alternative for CABG in the treatment of multivessel coronary artery disease in a selected patient population.

Citing Articles

Mid-term follow-up outcomes of 2-staged hybrid coronary revascularization compared with off-pump coronary artery bypass for patients with multivessel coronary artery disease.

Wu S, Ling Y, Fu Y, Zhang L, Yang H, Guo L Wideochir Inne Tech Maloinwazyjne. 2017; 12(2):178-185.

PMID: 28694905 PMC: 5502332. DOI: 10.5114/wiitm.2017.66803.


Hybrid coronary revascularization: present indications and future perspective.

Voudris K, Avgerinos D, Feldman D, Charitakis K Curr Treat Options Cardiovasc Med. 2015; 17(3):364.

PMID: 25708975 DOI: 10.1007/s11936-015-0364-3.

References
1.
Hu S, Li Q, Gao P, Xiong H, Zheng Z, Li L . Simultaneous hybrid revascularization versus off-pump coronary artery bypass for multivessel coronary artery disease. Ann Thorac Surg. 2011; 91(2):432-8. DOI: 10.1016/j.athoracsur.2010.10.020. View

2.
Gilard M, Bezon E, Cornily J, Mansourati J, Mondine P, Barra J . Same-day combined percutaneous coronary intervention and coronary artery surgery. Cardiology. 2007; 108(4):363-7. DOI: 10.1159/000099110. View

3.
. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996; 335(4):217-25. DOI: 10.1056/NEJM199607253350401. View

4.
Gao C, Yang M, Wu Y, Wang G, Xiao C, Liu H . Hybrid coronary revascularization by endoscopic robotic coronary artery bypass grafting on beating heart and stent placement. Ann Thorac Surg. 2009; 87(3):737-41. DOI: 10.1016/j.athoracsur.2008.12.017. View

5.
Guyton R . Coronary artery bypass is superior to drug-eluting stents in multivessel coronary artery disease. Ann Thorac Surg. 2006; 81(6):1949-57. DOI: 10.1016/j.athoracsur.2006.03.020. View